A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.

被引：2
|
作者：
Krishnan, Amrita Y.
Shah, Nina
Spira, Alexander I.
Kaufman, Jonathan L.
Niesvizky, Ruben
Shah, Nirav Niranjan
Burke, John M.
Popplewell, Leslie
Martin, Thomas G.
Cheung, Julee
Matheny, Shannon L.
Leonard, John Paul
Molina, Arturo
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Virginia Canc Specialists, Fairfax, VA USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] New York Presbyterian Hosp, Cornell Campus, New York, NY USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Rocky Mt Canc Ctr, Aurora, CO USA
[8] Sutro Biopharma, San Francisco, CA USA
[9] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS7586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7586
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.
    Adjei, Alex A.
    Bekaii-Saab, Tanios S.
    Berlin, Jordan
    Philip, Agop Philip
    Mercade, Teresa Macarulla
    Walter, Annette
    Cupit, Lisa
    Liu, Rong
    Fields, Scott Z.
    Holynskyj, Ariadna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma
    Lesokhin, Alexander M.
    Raje, Noopur
    Gasparetto, Cristina J.
    Walker, Justine
    Krupka, Heike I.
    Joh, Tenshang
    Taylor, Carrie T.
    Jakubowiak, Andrzej
    BLOOD, 2018, 132
  • [33] An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
    RA Eisenberg
    S Khan
    J Stansberry
    D Tsai
    S Kolasinski
    E Rieder
    B Kotzin
    RJ Looney
    C Strieber
    D Albert
    Arthritis Res Ther, 6 (Suppl 3):
  • [34] OPEN-LABEL, PHASE 1 SAFETY AND PHARMACOKINETIC STUDY TO EVALUATE RUCAPARIB IN JAPANESE PATIENTS WITH A PREVIOUSLY TREATED ADVANCED SOLID TUMOUR
    Tamura, K.
    Matsumoto, K.
    Hasegawa, K.
    Nishikawa, T.
    Shimomura, A.
    Sudo, K.
    Isaacson, J.
    Jones, E.
    Giordano, H.
    Fujiwara, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 1021 - 1021
  • [35] An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data
    Ogura, Michinori
    Hatake, Kiyohiko
    Davies, Andrew
    Crump, Michael
    Tobinai, Kensei
    Smith, Mitchell R.
    Offner, Fritz
    Wang, Shaw-Ling
    Ishibashi, Taro
    Paccagnella, Luisa
    Vandendries, Erik
    MacDonald, David A.
    BLOOD, 2012, 120 (21)
  • [36] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
    Hamid, O.
    Chow, L. Q.
    Sanborn, R. E.
    Marshall, S.
    Black, C.
    Gribbin, M.
    McDevitt, J.
    Karakunnel, J. J.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
    Wang, Xicheng
    Zhou, Jianfeng
    Li, Yan
    Ge, Yuping
    Zhou, Yanping
    Bai, Chunmei
    Shen, Lin
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2020, 12 : 21 - 33
  • [38] An open-label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced hematological malignancies
    Knurowski, Tomasz
    Searle, Emma
    Clegg, Karen
    Pegg, Neil
    West, William
    Haynes, Debbie
    Frese, Kristopher
    Somervaille, Tim C.
    CANCER RESEARCH, 2023, 83 (08)
  • [39] Praluzatamab Ravtansine, a CD166-Targeting Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
    Boni, Valentina
    Fidler, Mary J.
    Arkenau, Hendrik-Tobias
    Spira, Alexander
    Meric-Bernstam, Funda
    Uboha, Nataliya
    Sanborn, Rachel E.
    Sweis, Randy F.
    LoRusso, Patricia
    Nagasaka, Misako
    Garcia-Corbacho, Javier
    Jalal, Shadia
    Harding, James J.
    Kim, Stella K.
    Miedema, Iris H. C.
    Vugts, Danielle J.
    Huisman, Marc C.
    Zwezerijnen, Gerben J. C.
    van Dongen, Guus A. M. S.
    van Oordt, C. Willemien Menke van der Houven
    Wang, Song
    Dang, Tam
    Zein, Ivan A.
    Vasiljeva, Olga
    Lyman, Susan K.
    Paton, Virginia
    Hannah, Alison
    Liu, Joyce F.
    CLINICAL CANCER RESEARCH, 2022, 28 (10) : 2020 - 2029
  • [40] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
    Hamid, Omid
    Chow, Laura Quan Man
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345